---
document_datetime: 2025-12-02 05:04:16
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/afinitor.html
document_name: afinitor.html
version: success
processing_time: 0.1263173
conversion_datetime: 2025-12-24 04:23:34.618974
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Afinitor

[RSS](/en/individual-human-medicine.xml/65688)

##### Authorised

This medicine is authorised for use in the European Union

everolimus Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Afinitor](#news-on)
- [More information on Afinitor](#more-information-on-afinitor-502)
- [More information on Afinitor](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Afinitor is a cancer medicine used to treat the following cancers:

- breast cancer that is advanced (has started to spread) in women who have been through their menopause. Afinitor is used in breast cancer that is 'hormone receptor-positive' (when the cancer cells have oestrogen receptors on their surface) and 'HER2/neu negative' (when the cancer cells do not contain high levels of the HER2/neu [human epidermal growth factor receptor-2] protein). Afinitor is used together with a medicine called exemestane after other treatments called 'non-steroidal aromatase inhibitors' have not worked;
- pancreatic neuroendocrine tumours (tumours of the hormone-producing cells in the pancreas) when the cancer cells are well- or moderately differentiated (which means that they can be distinguished from normal pancreas cells). It is used when the cancer is metastatic (has spread to other parts of the body) or when it cannot be surgically removed;
- neuroendocrine tumours originating in the lungs or gut, when the cancer cells are well-differentiated and the cancer is metastatic or cannot be removed by surgery.
- advanced renal cell carcinoma (a kidney cancer), when the cancer has worsened despite treatment with a 'VEGF-targeted' medicine (a type of medicine that blocks the effects of vascular endothelial growth factor proteins).

Afinitor contains the active substance everolimus.

Expand section

Collapse section

## How is Afinitor used?

Afinitor can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the use of cancer treatments.

Afinitor is available as tablets (2.5, 5 and 10 mg) and the recommended dose is 10 mg once a day. Treatment should continue for as long as it works or until side effects become unacceptable. The doctor may reduce the dose or stop treatment for a short period if the patient has severe or intolerable side effects. Doses need to be reduced for patients with liver problems.

The tablets should be taken at the same time every day and consistently with or without food.

For more information about using Afinitor, see the package leaflet or contact your doctor or pharmacist.

## How does Afinitor work?

The active substance in Afinitor, everolimus, blocks an enzyme called 'mammalian target of rapamycin' (mTOR). In the body, everolimus first attaches to a protein called FKBP-12 that is found inside cells to make a 'complex'. This complex then blocks mTOR. Since mTOR is involved in the control of cell division and the growth of blood vessels, Afinitor prevents the division of cancer cells and reduces their blood supply. This slows down the growth and spread of the cancer.

## What benefits of Afinitor have been shown in studies?

**Breast cancer**

Afinitor in combination with exemestane has been studied in 724 patients with hormone receptor-positive and HER2/neu-negative advanced breast cancer which had got worse after treatment with letrozole and anastrazole (non-steroidal aromatase inhibitors). Patients who took Afinitor lived for an average of 7.8 months without their disease getting worse, compared with 3.2 months for the patients who took placebo (a dummy treatment).

**Pancreatic neuroendocrine tumours**

A study in 410 patients with advanced well- or moderately differentiated neuroendocrine tumours of pancreatic origin compared Afinitor with placebo. Patients who took Afinitor lived for an average of 11.0 months without the disease getting worse, compared with 4.6 months for the patients who took placebo.

**Neuroendocrine tumours originating in the lung or gut**

Afinitor was studied in 302 patients with advanced neuroendocrine tumours of lung or gut origin. Patients who received Afinitor and best supportive treatments lived for an average of 11 months without the disease getting worse compared with around 4 months for patients who received placebo and best supportive treatments to relieve disease symptoms.

**Renal cell carcinoma**

Afinitor was studied in 416 patients with advanced renal cell carcinoma that had got worse despite treatment with VEGF-targeted medicines (sunitinib, sorafenib or both). Patients who took Afinitor lived for an average of 4.9 months without the disease getting worse, compared with 1.9 months for the patients who took placebo.

## What are the risks associated with Afinitor?

The most common side effects with Afinitor (which may affect more than 1 in 10 people) are rash, itching, nausea, decreased appetite, dysgeusia (taste disturbances), headache, weight loss, peripheral oedema (swelling, especially of the ankles and feet), cough, anaemia (low red blood cell counts), tiredness, diarrhoea, weakness, infections, stomatitis (inflammation of the lining of the mouth), hyperglycaemia (high blood glucose levels), hypercholesterolaemia (high blood cholesterol levels), pneumonitis (inflammation of the lungs) and nosebleeds. For the full list of side effects of Afinitor, see the package leaflet.

Afinitor must not be used in people who are hypersensitive (allergic) to other rapamycin derivatives (substances with a similar structure to everolimus) or to any of the other ingredients. For the full list of restrictions, see the package leaflet.

## Why is Afinitor authorised in the EU?

The European Medicines Agency decided that Afinitor's benefits are greater than its risks and it can be authorised for use in the EU. Afinitor slowed down disease progression in patients with advanced neuroendocrine tumours of pancreatic origin, advanced renal cell carcinoma and hormone-receptor-positive advanced breast cancer. The Agency also concluded that the 7-month delay in disease progression for patients with neuroendocrine tumours originating in the lungs or gut was valuable, despite the known side effects of Afinitor.

## What extra measures are being taken to ensure the safe and effective use of Afinitor?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Afinitor have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Afinitor are continuously monitored. Side effects reported with Afinitor are carefully evaluated and any necessary action taken to protect patients.

## Other information about Afinitor

Afinitor received a marketing authorisation valid throughout the EU on 03 August 2009 *.*

Afinitor : EPAR - Summary for the public

Reference Number: EMA/44790/2013

English (EN) (86.6 KB - PDF)

**First published:** 15/04/2010

**Last updated:** 11/12/2018

[View](/en/documents/overview/afinitor-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-272)

български (BG) (114 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/bg/documents/overview/afinitor-epar-summary-public_bg.pdf)

español (ES) (84.34 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/es/documents/overview/afinitor-epar-summary-public_es.pdf)

čeština (CS) (111.45 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/cs/documents/overview/afinitor-epar-summary-public_cs.pdf)

dansk (DA) (83.21 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/da/documents/overview/afinitor-epar-summary-public_da.pdf)

Deutsch (DE) (85.58 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/de/documents/overview/afinitor-epar-summary-public_de.pdf)

eesti keel (ET) (83.04 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/et/documents/overview/afinitor-epar-summary-public_et.pdf)

ελληνικά (EL) (114.43 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/el/documents/overview/afinitor-epar-summary-public_el.pdf)

français (FR) (85.13 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/fr/documents/overview/afinitor-epar-summary-public_fr.pdf)

hrvatski (HR) (125.92 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/hr/documents/overview/afinitor-epar-summary-public_hr.pdf)

italiano (IT) (83.93 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/it/documents/overview/afinitor-epar-summary-public_it.pdf)

latviešu valoda (LV) (114.92 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/lv/documents/overview/afinitor-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (109.07 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/lt/documents/overview/afinitor-epar-summary-public_lt.pdf)

magyar (HU) (107.89 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/hu/documents/overview/afinitor-epar-summary-public_hu.pdf)

Malti (MT) (112.8 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/mt/documents/overview/afinitor-epar-summary-public_mt.pdf)

Nederlands (NL) (84.03 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/nl/documents/overview/afinitor-epar-summary-public_nl.pdf)

polski (PL) (110.68 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/pl/documents/overview/afinitor-epar-summary-public_pl.pdf)

português (PT) (84.57 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/pt/documents/overview/afinitor-epar-summary-public_pt.pdf)

română (RO) (106.95 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/ro/documents/overview/afinitor-epar-summary-public_ro.pdf)

slovenčina (SK) (109.23 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/sk/documents/overview/afinitor-epar-summary-public_sk.pdf)

slovenščina (SL) (105.23 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/sl/documents/overview/afinitor-epar-summary-public_sl.pdf)

Suomi (FI) (82.95 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/fi/documents/overview/afinitor-epar-summary-public_fi.pdf)

svenska (SV) (83.49 KB - PDF)

**First published:**

15/04/2010

**Last updated:**

11/12/2018

[View](/sv/documents/overview/afinitor-epar-summary-public_sv.pdf)

Afinitor : EPAR - Risk-management-plan summary

English (EN) (81.17 KB - PDF)

**First published:** 25/02/2020

**Last updated:** 07/12/2021

[View](/en/documents/rmp-summary/afinitor-epar-risk-management-plan-summary_en.pdf)

## Product information

Afinitor : EPAR - Product information

English (EN) (665 KB - PDF)

**First published:** 02/09/2009

**Last updated:** 20/11/2025

[View](/en/documents/product-information/afinitor-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-239)

български (BG) (750.46 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/bg/documents/product-information/afinitor-epar-product-information_bg.pdf)

español (ES) (668.57 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/es/documents/product-information/afinitor-epar-product-information_es.pdf)

čeština (CS) (732.6 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/cs/documents/product-information/afinitor-epar-product-information_cs.pdf)

dansk (DA) (682.53 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/da/documents/product-information/afinitor-epar-product-information_da.pdf)

Deutsch (DE) (685.02 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/de/documents/product-information/afinitor-epar-product-information_de.pdf)

eesti keel (ET) (658.09 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/et/documents/product-information/afinitor-epar-product-information_et.pdf)

ελληνικά (EL) (806.57 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/el/documents/product-information/afinitor-epar-product-information_el.pdf)

français (FR) (738.82 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/fr/documents/product-information/afinitor-epar-product-information_fr.pdf)

hrvatski (HR) (725.5 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/hr/documents/product-information/afinitor-epar-product-information_hr.pdf)

íslenska (IS) (650.33 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/is/documents/product-information/afinitor-epar-product-information_is.pdf)

italiano (IT) (708.35 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/it/documents/product-information/afinitor-epar-product-information_it.pdf)

latviešu valoda (LV) (738.87 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/lv/documents/product-information/afinitor-epar-product-information_lv.pdf)

lietuvių kalba (LT) (738.13 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/lt/documents/product-information/afinitor-epar-product-information_lt.pdf)

magyar (HU) (723.22 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/hu/documents/product-information/afinitor-epar-product-information_hu.pdf)

Malti (MT) (764.74 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/mt/documents/product-information/afinitor-epar-product-information_mt.pdf)

Nederlands (NL) (682.27 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/nl/documents/product-information/afinitor-epar-product-information_nl.pdf)

norsk (NO) (684.47 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/no/documents/product-information/afinitor-epar-product-information_no.pdf)

polski (PL) (732.43 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/pl/documents/product-information/afinitor-epar-product-information_pl.pdf)

português (PT) (695.01 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/pt/documents/product-information/afinitor-epar-product-information_pt.pdf)

română (RO) (712.72 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/ro/documents/product-information/afinitor-epar-product-information_ro.pdf)

slovenčina (SK) (714.25 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/sk/documents/product-information/afinitor-epar-product-information_sk.pdf)

slovenščina (SL) (714.28 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/sl/documents/product-information/afinitor-epar-product-information_sl.pdf)

Suomi (FI) (653.67 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/fi/documents/product-information/afinitor-epar-product-information_fi.pdf)

svenska (SV) (648.04 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

20/11/2025

[View](/sv/documents/product-information/afinitor-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000310437 20/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Afinitor : EPAR - All Authorised presentations

English (EN) (108.17 KB - PDF)

**First published:** 02/09/2009

**Last updated:** 12/06/2014

[View](/en/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-812)

български (BG) (159.2 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/bg/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_bg.pdf)

español (ES) (109.38 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/es/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_es.pdf)

čeština (CS) (111.85 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/cs/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (151.38 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/da/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (110.4 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/de/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (150.82 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/et/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (115.58 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/el/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_el.pdf)

français (FR) (152.91 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/fr/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (110.54 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/hr/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (151.54 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/is/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_is.pdf)

italiano (IT) (150.53 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/it/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (112.42 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/lv/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (113.89 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/lt/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (114.4 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/hu/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (112.08 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/mt/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (150.82 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/nl/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (108.9 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/no/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_no.pdf)

polski (PL) (152.86 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/pl/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_pl.pdf)

português (PT) (108.47 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/pt/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_pt.pdf)

română (RO) (112.03 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/ro/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (113.07 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/sk/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (109.28 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/sl/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (109.41 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/fi/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (150.87 KB - PDF)

**First published:**

02/09/2009

**Last updated:**

12/06/2014

[View](/sv/documents/all-authorised-presentations/afinitor-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Afinitor Active substance everolimus International non-proprietary name (INN) or common name everolimus Therapeutic area (MeSH)

- Carcinoma, Renal Cell
- Breast Neoplasms
- Pancreatic Neoplasms

Anatomical therapeutic chemical (ATC) code L01XE10

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

**Hormone-receptor-positive advanced breast cancer**

Afinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.

**Neuroendocrine tumours of pancreatic origin**

Afinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.

**Neuroendocrine tumours of gastrointestinal or lung origin**

Afinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.

**Renal-cell carcinoma**

Afinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.

## Authorisation details

EMA product number EMEA/H/C/001038 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Marketing authorisation issued 02/08/2009 Revision 33

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Afinitor : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (127.09 KB - PDF)

**First published:** 28/08/2025

**Last updated:** 20/11/2025

[View](/en/documents/procedural-steps-after/afinitor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Afinitor : EPAR - Procedural steps taken and scientific information after authorisation (archived)

English (EN) (291.41 KB - PDF)

**First published:** 15/04/2010

**Last updated:** 22/11/2024

[View](/en/documents/procedural-steps-after/afinitor-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf)

Afinitor-H-C-1038-II-0048 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/390543/2016

English (EN) (3.35 MB - PDF)

**First published:** 21/07/2016

**Last updated:** 21/07/2016

[View](/en/documents/variation-report/afinitor-h-c-1038-ii-0048-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Afinitor

Adopted

Reference Number: EMA/CHMP/269366/2016

English (EN) (70.31 KB - PDF)

**First published:** 29/04/2016

**Last updated:** 29/04/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-afinitor_en.pdf-0)

Afinitor-H-C-1038-PSUV-0039 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/794249/2014

English (EN) (66 KB - PDF)

**First published:** 23/12/2014

**Last updated:** 23/12/2014

[View](/en/documents/scientific-conclusion/afinitor-h-c-1038-psuv-0039-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Afinitor-H-C-1038-II-0020 : EPAR - Assessment Report - Variation

Reference Number: EMA/CHMP/438808/2012

English (EN) (2.67 MB - PDF)

**First published:** 07/08/2012

**Last updated:** 07/08/2012

[View](/en/documents/variation-report/afinitor-h-c-1038-ii-0020-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Afinitor

Adopted

Reference Number: EMA/CHMP/402772/2012

English (EN) (48.07 KB - PDF)

**First published:** 22/06/2012

**Last updated:** 22/06/2012

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-afinitor_en.pdf-1)

Afinitor-H-C-1038-II-0008: EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/723893/2011

English (EN) (1.28 MB - PDF)

**First published:** 29/09/2011

**Last updated:** 29/09/2011

[View](/en/documents/variation-report/afinitor-h-c-1038-ii-0008-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Afinitor

Adopted

Reference Number: EMA/CHMP/591153/2011

English (EN) (66.53 KB - PDF)

**First published:** 22/07/2011

**Last updated:** 22/07/2011

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-afinitor_en.pdf)

## Initial marketing authorisation documents

Afinitor : EPAR - Public assessment report

English (EN) (1.84 MB - PDF)

**First published:** 02/09/2009

**Last updated:** 02/09/2009

[View](/en/documents/assessment-report/afinitor-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use summary of positive opinion  for Afinitor

Reference Number: EMEA/CHMP/269077/2009

English (EN) (32.35 KB - PDF)

**First published:** 29/05/2009

**Last updated:** 29/05/2009

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-afinitor_en.pdf)

#### News on Afinitor

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 April 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-april-2016) 29/04/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 June 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-june-2012) 22/06/2012

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC001038II0048) (variation II/0048)

#### More information on Afinitor

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu307449) on 5 June 2007. Upon request of the marketing-authorisation holder, Afinitor has now been removed from the Community register of orphan medicinal products.

#### More information on Afinitor

- [EMEA-000019-PIP06-09-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000019-pip06-09-m05)
- [Breast Cancer Treatment with Afinitor® (Everolimus) and Exemestane for HR+ Women (BRAWO) - post-authorisation study](https://catalogues.ema.europa.eu/study/27127)
- [A phase IV multicentre, open-label, non-interventional study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with Afinitor® (everolimus RAD001) in combination with exemestane, after progression following therapy with a non-steroidal aromatase inhibitor (BOUDICA) - post-authorisation study](https://catalogues.ema.europa.eu/study/37830)
- [Observational prospective study in post-menopausal women with advanced HR+/HER2- breast cancer treated with a combination of Afinitor® + exemestane to describe the management of two Adverse Events, non-infectious lung disease and stomatitis (TANGO) - post-authorisation study](https://catalogues.ema.europa.eu/study/37868)

**This page was last updated on** 20/11/2025

## Share this page

[Back to top](#main-content)